Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

Completed · Phase 1

Conditions studied: Cancer

In brief

The goal of this study is to visualize biodistribution of a PET tracer called \[18F\]F-AraG through time in healthy human volunteers.

Key facts

Study ID

NCT02323893

Run by

CellSight Technologies, Inc.

People needed

6

Starts

2015-02-01

Expected to finish

2017-12-31

Last updated by the study team

2018-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy human subjects without history of chronic disease or at present an acute disease will be included.
• Ability to abide by the study conditions is also a requirement for inclusion.

You may not qualify if…

• Individuals under the age of 18 years and pregnant women will be excluded from the [18F]F-AraG imaging studies.
• Women who are breast-feeding will be excluded from the study.
• Individuals unable to provide informed consent will be excluded.

Where it is running

• UCSF Imaging Center at China Basin — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.